Tardiff Daniel 4

What Happened

• Daniel Tardiff, Chief Scientific Officer of Camp4 Therapeutics (CAMP), received a grant of 170,000 derivative shares on 2026-04-01. The Form 4 records the acquisition price as $0.00, indicating a compensation award rather than an open-market purchase. No exercise or sale occurred — this is an equity grant from the company for future compensation.

Key Details

• Transaction date and price: 2026-04-01, grant recorded at $0.00 per share.
• Shares granted: 170,000 (derivative award / option-style grant as noted in filing).
• Shares owned after transaction: Not specified in this Form 4 filing.
• Vesting: The filing footnote states the shares underlying the option vest in equal monthly installments over four years starting at the grant date (i.e., monthly vesting over 48 months).
• Filing date / timeliness: Form 4 was filed 2026-04-03; the filing shows no indication of a late filing.

Context

• This was a compensation grant (derivative award), not a purchase or sale — typical for executive pay. The award vests over time, so the shares are not immediately transferable. For retail investors, grants are common and reflect company compensation practices rather than a direct buy/sell signal.